by John A. Jenkins | Nov 6, 2024 | FDA, FOIA
FOIAengine: Media Requests Signaled Issues for a “Party Drug” Going Mainstream With 153 clinical trials to assess whether the party drug known as Ecstasy can help patients suffering from Post Traumatic Stress Disorder, optimism was high earlier this summer among...
by John A. Jenkins | Oct 31, 2024 | FDA, FOIA, Law Firms, Litigation
FOIAengine: Hundreds of Requests About FDA’s Tobacco Regulation With cigarette makers battling for market dominance in a “smoke-free future,” legal and marketing battles are raging – and recent Freedom of Information Act requests may signal what’s coming next. Womble...
by Randy E. Miller | Oct 24, 2024 | FDA, FOIA, Law Firms, Litigation
FOIAengine: Questions from Siri & Glimstad Point to Possible Litigation Does radiation from cell phones and cell towers affect human health? There has long been controversy around this question, which the federal government has tried to put to rest by issuing...
by Randy E. Miller | Sep 18, 2024 | FDA, FOIA, Hedge Funds, Medical Devices
FOIAengine: FDA Inspections Prompt FOIA Requests When CEO Quentin Blackford of iRhythm Technologies, Inc. (NASDAQ: IRTC) began his earnings call on August 1, his wearable heart monitor technology company had survived five years of market ups and downs and had...
by John A. Jenkins | Sep 11, 2024 | FDA, FOIA, FTC, SEC
FOIAengine Explores the Widespread Use of “Neither Confirm Nor Deny” By John A. Jenkins We’re taking a look this week at a frequently used Freedom of Information Act exemption that isn’t mentioned anywhere in the statutory language. It’s known as “Glomar” among the...
by Randy E. Miller | Jul 3, 2024 | FDA, FOIA, Law Firms, Litigation, Pharmaceuticals
FOIAengine: Law Firm’s 48 Inquiries Follow Earlier Requests Personal injury law firm Morgan & Morgan continued to push the Food and Drug Administration during May for documents that could strengthen potential litigation challenging popular weight control drugs. ...
